unexpected, life-threatening complication not described. 
5.7.4 Patient non-compliance with study medication and/or 
clinic appointments. 
5.7.5 Rapid or life-threatening progression of Kaposi's 
sarcoma such that institution of systemic anti-tumor 
therapy (such as chemotherapy or radiation therapy) 
would be in the patient's best interest, as determined by 
the principal investigator. 
5.7.6 Voluntary withdrawal: a patient may remove him/herself 
from study at any time without prejudice. 
5.7.7 Termination of the study by the principal investigator or 
the F.D.A. 
6.0 Study Endpoints 
6.1 Death 
6.2 Grade IV toxicity 
6.3 Voluntary withdrawal by the patient 
6.4 Judgment by the PI that termination of treatment is in the 
best interest of the patient. 
7.0 Statistical Analysis 
Demographic, medical history, and physical examination data 
obtained at the preadmission (baseline) visit will be listed for each 
patient in the study. All patients receiving adoptive transfers will be 
included in the safety analysis. Adverse reaction or complaint data 
Recombinant DNA Research, Volume 16 
[309] 
